Federated Investors Inc Decreased Corcept Therapeutics Inc (NASDAQ:CORT) Stake By $11.50 Million

August 12, 2018 - By Kyle Williams

Corcept Therapeutics Incorporated (NASDAQ:CORT) LogoInvestors sentiment decreased to 1.28 in 2018 Q1. Its down 0.21, from 1.49 in 2017Q4. It dropped, as 28 investors sold CORT shares while 55 reduced holdings. 46 funds opened positions while 60 raised stakes. 84.82 million shares or 2.95% less from 87.40 million shares in 2017Q4 were reported. Advisory Net Limited owns 47 shares. Alps Advsr has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT). 3,355 are held by Crow Point Prtn Limited Liability Co. Manufacturers Life Insur Com The reported 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Public Employees Retirement Association Of Colorado reported 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Schwab Charles Management has invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Tower Rech Capital Lc (Trc) stated it has 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Geode Mngmt Limited Liability Corporation accumulated 0% or 878,255 shares. Fifth Third Natl Bank reported 33,211 shares. The New York-based Consonance Capital Mgmt L P has invested 7.8% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Sector Pension Invest Board holds 61,600 shares. Clarivest Asset Mgmt Ltd stated it has 0.02% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Us Bancshares De invested 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Timpani Cap Ltd Liability reported 1.41% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Zebra Capital Management Ltd Company accumulated 62,746 shares or 0.37% of the stock.

Since March 6, 2018, it had 1 buying transaction, and 6 sales for $988,257 activity. Shares for $480,312 were sold by BAKER G LEONARD JR on Friday, May 11. Another trade for 10,000 shares valued at $155,102 was made by GALA RENEE D on Tuesday, March 6.

Federated Investors Inc decreased its stake in Corcept Therapeutics Inc (NASDAQ:CORT) by 6.04% based on its latest 2018Q2 regulatory filing with the SEC. Federated Investors Inc sold 766,619 shares as the company’s stock rose 20.10% while stock markets declined. The institutional investor held 11.92M shares of the major pharmaceuticals company at the end of 2018Q2, valued at $187.38 million, down from 12.69M at the end of the previous reported quarter. Federated Investors Inc who had been investing in Corcept Therapeutics Inc for a number of months, seems to be less bullish one the $1.53B market cap company. The stock decreased 5.15% or $0.72 during the last trading session, reaching $13.26. About 4.15M shares traded or 227.23% up from the average. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 60.38% since August 13, 2017 and is uptrending. It has outperformed by 47.81% the S&P500.

Federated Investors Inc, which manages about $34.12B US Long portfolio, upped its stake in Halliburton Co (NYSE:HAL) by 621,750 shares to 906,998 shares, valued at $40.87M in 2018Q2, according to the filing. It also increased its holding in Tjx Cos Inc New (NYSE:TJX) by 159,386 shares in the quarter, for a total of 693,325 shares, and has risen its stake in Mondelez Intl Inc (NASDAQ:MDLZ).

Federated Investors Inc is a Pennsylvania-based institutional investor with more than $254.00 billion AUM in March, 2014. This fund invests only a small percentage of its assets in equities and options. Federated Investors Inc is the 12th largest institutional investor in our database. Taken from Federated Investors latest Adv, the fund reported to have 93 full and part-time employees. Among which 91 performing investment advisory and research functions. The institutional investor had more than 107 clients.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

Among 4 analysts covering Corcept Therapeutics Inc (NASDAQ:CORT), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Corcept Therapeutics Inc had 7 analyst reports since March 8, 2018 according to SRatingsIntel. FBR Capital maintained it with “Buy” rating and $3000 target in Tuesday, June 19 report. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) has “Buy” rating given on Tuesday, June 12 by FBR Capital. The rating was initiated by Seaport Global on Friday, April 13 with “Buy”. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) has “Hold” rating given on Thursday, May 31 by Stifel Nicolaus. The company was maintained on Tuesday, March 20 by FBR Capital. The firm has “Buy” rating by FBR Capital given on Thursday, March 8.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $1.53 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 11.73 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

More notable recent Corcept Therapeutics Incorporated (NASDAQ:CORT) news were published by: Streetinsider.com which released: “After-Hours Stock Movers 08/09: (TTD) (OSTK) (PBYI) Higher; (CORT) (XONE) (DBX) Lower (more…)” on August 09, 2018, also Gurufocus.com with their article: “3 Stocks to Sell Friday” published on August 10, 2018, Benzinga.com published: “7 Stocks Moving In Thursday’s After-Hours Session” on August 09, 2018. More interesting news about Corcept Therapeutics Incorporated (NASDAQ:CORT) were released by: Seekingalpha.com and their article: “Should You Buy Corcept Therapeutics Before Earnings?” published on July 23, 2018 as well as Nasdaq.com‘s news article titled: “Corcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides …” with publication date: August 09, 2018.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.